Tumor growth inhibition by mSTEAP peptide nanovaccine inducing augmented CD8
Animals
Antigens, Neoplasm
/ administration & dosage
CD8-Positive T-Lymphocytes
/ drug effects
Cancer Vaccines
/ administration & dosage
Cell Line, Tumor
Liver
/ metabolism
Lung
/ metabolism
Male
Mice, Inbred C57BL
Nanoparticles
/ administration & dosage
Polylactic Acid-Polyglycolic Acid Copolymer
/ administration & dosage
Prostatic Neoplasms
/ drug therapy
Antigen-presenting cells
Antigenic peptide
Cancer immunotherapy
Nanovaccine
Poly(lactide-co-glycolide) acid
Journal
Drug delivery and translational research
ISSN: 2190-3948
Titre abrégé: Drug Deliv Transl Res
Pays: United States
ID NLM: 101540061
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
pubmed:
23
6
2019
medline:
2
4
2020
entrez:
23
6
2019
Statut:
ppublish
Résumé
Poly(lactic-co-glycolic) acid (PLGA) has been successfully used in drug delivery and biomaterial applications, but very little attention has been directed towards the potential in vivo effects of peptide-loaded PLGA nanoparticles (NPs), specifically the potency of intravenous (IV) STEAP peptide-loaded PLGA-NP (nanovaccine) dosing and whether STEAP-specific CD8
Identifiants
pubmed: 31228097
doi: 10.1007/s13346-019-00652-z
pii: 10.1007/s13346-019-00652-z
doi:
Substances chimiques
Antigens, Neoplasm
0
Cancer Vaccines
0
Steap protein, mouse
0
Polylactic Acid-Polyglycolic Acid Copolymer
1SIA8062RS
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1095-1105Références
Hum Vaccin Immunother. 2016 Apr 2;12(4):1056-69
pubmed: 26752261
Cancers (Basel). 2019 Feb 14;11(2):null
pubmed: 30769871
Am J Cancer Res. 2018 Jun 01;8(6):916-931
pubmed: 30034931
Vaccine. 2012 Oct 19;30(47):6609-11
pubmed: 23067445
Nat Nanotechnol. 2007 Dec;2(12):751-60
pubmed: 18654426
Prostate. 2016 Apr;76(5):456-68
pubmed: 26715028
Int J Cancer. 2004 Nov 1;112(2):335-40
pubmed: 15352049
Eur J Pharm Biopharm. 2013 Apr;83(3):338-45
pubmed: 23201055
Cancer Immunol Immunother. 2016 Jun;65(6):701-13
pubmed: 27052571
Oncoimmunology. 2015 Aug 12;5(1):e1068493
pubmed: 26942088
Nat Immunol. 2015 Jan;16(1):36-44
pubmed: 25521683
Adv Drug Deliv Rev. 2005 Jan 10;57(3):475-82
pubmed: 15560953
Int J Nanomedicine. 2012;7:1475-87
pubmed: 22619507
Immunology. 2017 Nov;152(3):462-471
pubmed: 28664991
J Biomed Sci. 2017 Mar 21;24(1):21
pubmed: 28320393
Cancer Res. 2016 Jul 1;76(13):3711-8
pubmed: 27216195
Colloids Surf B Biointerfaces. 2005 Mar 25;41(2-3):117-20
pubmed: 15737536
Clin Cancer Res. 2005 Jun 15;11(12):4545-52
pubmed: 15958640
Adv Exp Med Biol. 2018;1096:185-194
pubmed: 30324354
J Transl Med. 2011 Nov 05;9:191
pubmed: 22053850
Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18636-41
pubmed: 18003899
Immune Netw. 2013 Feb;13(1):30-3
pubmed: 23559898
Vaccine. 2008 Sep 15;26(39):5046-57
pubmed: 18680779
Core Evid. 2014 Dec 18;10:1-10
pubmed: 25565923
Sci Rep. 2015 Jun 03;5:10881
pubmed: 26039249
Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14523-8
pubmed: 10588738
Int Immunopharmacol. 2017 Jun;47:159-165
pubmed: 28410529
Cell. 2015 Apr 9;161(2):201-4
pubmed: 25860604
Vaccine. 2013 Jan 11;31(4):596-602
pubmed: 23219438
PLoS One. 2013 Apr 22;8(4):e62500
pubmed: 23614052
Nanotechnology. 2012 Aug 17;23(32):325101
pubmed: 22824940
Cells. 2017 Dec 07;6(4):null
pubmed: 29215603
Clin Transl Oncol. 2015 May;17(5):339-57
pubmed: 25480118
Immunotargets Ther. 2017 Mar 20;6:11-16
pubmed: 28361045
N Engl J Med. 2004 Oct 7;351(15):1502-12
pubmed: 15470213
J Transl Med. 2011 Mar 31;9:34
pubmed: 21450109
BMC Biol. 2017 Jun 29;15(1):53
pubmed: 28662662
J Urol. 2010 May;183(5):2036-44
pubmed: 20303532
Cancer Immunol Immunother. 2006 Dec;55(12):1515-23
pubmed: 16622681
Prostate Int. 2018 Dec;6(4):119-125
pubmed: 30505813
J Biomed Sci. 2015 Oct 20;22:89
pubmed: 26482775
Curr Pharm Des. 2018;24(43):5164-5174
pubmed: 30657037
Nanomedicine (Lond). 2018 Apr;13(8):913-928
pubmed: 29527969
Clin Exp Vaccine Res. 2014 Jul;3(2):113-6
pubmed: 25003083